Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma
M Hellmann, N Rizvi, JD Wolchok… - Molecular & Cellular …, 2016 - Taylor & Francis
Molecular & Cellular Oncology, 2016•Taylor & Francis
The recent successes of immune checkpoint therapies have established a new era for the
treatment of patients with cancer, yet the predictors of response remain largely
undetermined. We recently demonstrated that the genomic landscape of lung cancers
substantially influences the response to programmed cell death 1 receptor (PD-1) blockade,
providing new insights into the molecular determinants of the response to immunotherapy.
treatment of patients with cancer, yet the predictors of response remain largely
undetermined. We recently demonstrated that the genomic landscape of lung cancers
substantially influences the response to programmed cell death 1 receptor (PD-1) blockade,
providing new insights into the molecular determinants of the response to immunotherapy.
Abstract
The recent successes of immune checkpoint therapies have established a new era for the treatment of patients with cancer, yet the predictors of response remain largely undetermined. We recently demonstrated that the genomic landscape of lung cancers substantially influences the response to programmed cell death 1 receptor (PD-1) blockade, providing new insights into the molecular determinants of the response to immunotherapy.
Taylor & Francis Online